Shenzhen Haiwang Biotechnology Co., Ltd. (stock code: 000078) is a high-tech enterprise focusing on R&D, production and sales of biomedicine and health products. The company is committed to continuously improving its core competitiveness and providing customers with high-quality health products and services through technological innovation and product upgrades. In the first quarter of 2024, Neptune Biotech released its latest financial report. This article will analyze its financial data in detail.
The total assets of Neptune Biotech in the first quarter of 2024 were 32,662 billion yuan, an increase of 1.11% over 32.305 billion yuan at the end of the previous year. Owners' equity attributable to shareholders of listed companies was 3,046 billion yuan, an increase of 1.42% over the 3.03 billion yuan at the end of the previous year. The balance ratio rose slightly to 86.97% from 86.94% at the end of the previous year. These data show that Neptune Biotech has maintained steady growth in terms of asset size and shareholders' equity, but the slight increase in balance ratio also suggests that the company needs further optimization in terms of debt management.
In terms of profit, Neptune Biotech's revenue was 8.088 billion yuan, a year-on-year decrease of 18.78%. Net profit attributable to shareholders of listed companies was 42.64 million yuan, a year-on-year decrease of 42.79%. However, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 47.37 million yuan, an increase of 6.48% over the previous year. This indicates that although overall revenue and net profit have declined, net profit after deducting non-recurring profit and loss has increased, indicating an increase in the profitability of the company's main business. Gross margin fell to 10.42% from 10.69% in the same period last year, and net margin fell from 1.11% to 0.86%, reflecting the company's continued need to strengthen cost control and profitability.
In terms of cash flow, the net cash flow from Haiwang Biotech's operating activities was 56.76 million yuan, a year-on-year decrease of 48.16%. The total cash inflow from operating activities was 9.411 billion yuan, a slight decrease from the previous year, while the cash outflow subtotal was 9.355 billion yuan, a slight increase over the previous year. This was mainly due to the decline in the company's sales payback. Net cash flow from investing activities increased 36.76% year over year, mainly due to a decrease in outstanding equity payments in the current period. Net cash flow from financing activities decreased by 147.66% year over year, mainly due to repayment of bank loans in the current period. These data show that the company is under some pressure in terms of cash flow from operating activities, but there have been improvements in investment and financing activities.
In summary, Neptune Biotech's financial performance in the first quarter of 2024 presented certain challenges and opportunities. It has maintained steady growth in assets and shareholders' equity, but is under pressure in terms of revenue and net profit. The company needs further optimization in terms of cost control, profitability, and cash flow management to cope with market changes and competitive pressures. In the future, Neptune Biotech should continue to strengthen technological innovation and product upgrades, enhance core competitiveness, and achieve sustainable development.